Skip to main content
. 2023 Nov 11;9(2):423–435. doi: 10.1016/j.ekir.2023.11.003

Figure 4.

Figure 4

JAK2 inhibitor AZD1480 alone does not affect production of Gd-IgA1 in IgA1-secreting tonsillar cell lines. (a) Gd-IgA1 production by tonsillar IgA1-producing cell lines from patients with OSA and IgAN was evaluated in the absence and presence of AZD1480 (3–300 nM). AZD 1480 did not change baseline levels of Gd-IgA1 in the tested cell lines. (b) Representative western blot of phosphorylation of STAT1 (pSTAT1) and total STAT1 in the absence or presence of AZD1480 (3–300 nM) in mock-stimulated tonsillar IgA1-producing cells. Baseline phosphorylation of STAT1 was inhibited by treatment of AZD1480 in a dose-dependent manner. Actin blot is shown as an additional control for protein load. (c) Densitometric analysis of pSTAT1 immunoblot data from panel b was performed in all samples (n = 3 in each group). pSTAT1 relative to total STAT1 level in OSA (control) was set to 1. All data are presented as mean ± SD values and mean values for individual cell lines are shown by black circles. ∗P < 0.05, ∗∗P < 0.01. IgAN, IgA nephropathy; ns, not statistically significant; OSA, obstructive sleep apnea.